Trials / Approved For Marketing
Approved For MarketingNCT02589717
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab [TECENTRIQ] | Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes. |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-10-28
- Last updated
- 2016-11-02
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02589717. Inclusion in this directory is not an endorsement.